Mode
Text Size
Log in / Sign up

IgA Nephropathy

Part of Nephritis

8 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for IgA Nephropathy

8 trials tracked for IgA Nephropathy: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 287 citations.

8Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 2 4 Phase 1 1 Other / NA 1
  1. Phase 4 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Completed · 287 cited
  2. Phase 4 Pilot Study of Velcade® in IgA Nephropathy Completed · 64 cited
  3. Phase 2 A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Completed
  4. Phase 2 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Completed
  5. Phase 2 Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy Completed
  6. Phase 2 Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation Completed
Show 2 more trials
  1. Phase 1 First in Human Study to Assess Safety of VIS649 in Healthy Subjects Completed
  2. N/A A Controlled Study of Uric Acid on the Progression of IgA Nephropathy Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Nephritis

Related studies from across the Nephritis family.

Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy
Allergy & Immunology Sys. Review
Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy New Strategies Target Treatment Resistance in Membranous Nephropathy
This systematic review examines the multifactorial mechanisms of rituximab resistance in patients with primary membranous nephropathy. It id…
Researchers identify new ways to treat primary membranous nephropathy when standard rituximab treatments do not work.
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy
Drug Pipeline Sys. Review
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy A third Rituximab dose caused severe shock in a man with kidney disease
This case report describes a 52-year-old male with biopsy-proven primary membranous nephropathy who received a third 1 g infusion of rituxim…
A man with kidney disease developed life-threatening shock after a third Rituximab infusion, highlighting the need for careful monitoring an…
Narrative review discusses potential therapeutic roles of herbal compounds in membranous nephropathy
Urology Sys. Review
Narrative review discusses potential therapeutic roles of herbal compounds in membranous nephropathy Ancient Herbs Could Protect Kidneys From Autoimmune Damage
This narrative review explores the potential therapeutic roles of specific herbal compounds, including icariin and astragaloside IV, for mem…
Scientists are finding new ways to use natural plant compounds to protect damaged kidney filters.
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients
Dermatology Cohort
Obinutuzumab-guided regimen achieves high remission in refractory membranous nephropathy patients New Dosing Strategy Helps Kidney Disease Patients Who Didn’t Respond to Standard Treatment
This single-center retrospective cohort study evaluated 33 patients with refractory membranous nephropathy treated with a B-cell reconstitut…
For patients with a stubborn kidney disease who ran out of options, a smarter dosing strategy may offer a new path to recovery.
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Drug Pipeline Cohort
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Review of Traditional Chinese Botanical Medicine in Membranous Nephropathy
Drug Pipeline Meta-analysis
Review of Traditional Chinese Botanical Medicine in Membranous Nephropathy A review examines traditional Chinese medicine for kidney condition known as membranous nephropathy
This narrative review examines the use of Traditional Chinese Botanical Medicine (CHMs) and their active metabolites for membranous nephropa…
Traditional Chinese botanical medicines show promise for treating membranous nephropathy, but this review found no proof of their safety or …
Hispanic/Latinx adults with IgAN show rapid eGFR decline and high kidney event rates in retrospective cohort
Nephrology Cohort
Hispanic/Latinx adults with IgAN show rapid eGFR decline and high kidney event rates in retrospective cohort Study describes kidney disease progression in Hispanic adults with IgA nephropathy
A retrospective case series of 259 Hispanic/Latinx adults with biopsy-proven IgAN in a U.S.
Hispanic adults with IgA nephropathy face a rapid kidney function decline, with nearly one-third losing over 5 ml/min annually and reaching …
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case
Diabetes & Endocrinology Sys. Review
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case Rituximab treatment reduced kidney protein loss in one Sjögren's syndrome patient
A case report describes a 48-year-old female with primary Sjögren's syndrome and nephrotic-range proteinuria treated with prednisone and rit…
A 48-year-old woman with Sjögren's syndrome saw her kidney protein loss drop from 8.5 to 2.2 grams after receiving rituximab treatment.

Questions about IgA Nephropathy

Do podocyte changes predict albuminuria and kidney function decline in IgA nephropathy?

Yes, specific changes in podocyte shape and structure are linked to higher albumin levels and faster kidney function loss in IgA nephropathy.

Full answer →
Does telitacicept help reduce proteinuria in adults with IgA nephropathy?

Yes, telitacicept significantly reduces proteinuria in adults with IgA nephropathy, based on a Phase 3 trial and multiple real-world studies.

Full answer →
Can high cholesterol levels make kidney disease worse for patients with IgA nephropathy?

Yes, high cholesterol levels can worsen kidney disease in IgA nephropathy patients, as dyslipidemia is linked to poorer renal survival and more severe kidney damage.

Full answer →